Department of Neurology, Traditional Chinese Medicine Hospital, ChongQing, China.
Medicine (Baltimore). 2022 Sep 9;101(36):e30501. doi: 10.1097/MD.0000000000030501.
Lipid metabolism affects cell proliferation, differentiation, membrane homeostasis and drug resistance. An in-depth exploration of lipid metabolism in gliomas might provide a novel direction for gliomas treatment. A lipid metabolism-related risk signature was constructed in our study to assess the prognosis of patients with gliomas. Lipid metabolism-related genes were extracted. Differentially expressed genes (DEGs) were screened, and a risk signature was built. The ability of the risk signature to predict the outcomes of patients with gliomas was assessed using the log-rank test and Cox regression analysis. The relationships between immunological characteristics, drug sensitivity and the risk score were evaluated, and the risk-related mechanisms were also estimated. Twenty lipid metabolism-related DEGs associated with the patient prognosis were included in the risk signature. The survival rate of high-risk patients was worse than that of low-risk patients. The risk score independently predicted the outcomes of patients. Immunological parameters, drug sensitivity, immunotherapy benefits, and numerous molecular mechanisms were significantly associated with the risk score. A lipid metabolism-related risk signature might effectively assess the prognosis of patients with gliomas. The risk score might guide individualized treatment and further clinical decision-making for patients with gliomas.
脂质代谢影响细胞增殖、分化、膜稳态和耐药性。深入探索胶质瘤中的脂质代谢可能为胶质瘤的治疗提供新的方向。本研究构建了一个与脂质代谢相关的风险特征，以评估胶质瘤患者的预后。提取脂质代谢相关基因，筛选差异表达基因（DEGs），构建风险特征。使用对数秩检验和 Cox 回归分析评估风险特征预测胶质瘤患者结局的能力。评估免疫特征、药物敏感性与风险评分之间的关系，并估计风险相关机制。该风险特征包括 20 个与患者预后相关的脂质代谢差异表达基因。高危患者的生存率较 低危患者差。风险评分独立预测患者结局。免疫参数、药物敏感性、免疫治疗获益以及大量分子机制与风险评分显著相关。一个与脂质代谢相关的风险特征可以有效地评估胶质瘤患者的预后。风险评分可能为胶质瘤患者的个体化治疗和进一步的临床决策提供指导。
